Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mast cells, bone marrow fibrosis, and ruxolitinib response in myeloproliferative neoplasms
NL-OMON48689Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ruxolitinib in myeloproliferative disorder (MPD) (3 cohorts), sponsored by Erasmus MC. Primary endpoints: Bone marrow mast cell number in MPN, Mast cell phenotype and function and 5 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NL-OMON48689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48689.